Compounding snapshot: Get it now!

Semaglutide, tirzepatide, and more

Shortage Drug Compounding and GLP-1s: What you need to know

☞ On deadline? For media inquiries CLICK HERE. 

Upcoming Events

October 14-17: ISTX24: PCCA International Seminar, Houston

October 22: APC webinar with Pharmacists Mutual: Coverage, Claims, and Compounding: What You Need to Know About Your Liability Insurance

October 29: PCAC meeting on adding several bulk drug substances to the 503A Bulks List (1 of 2)

November 7: APC webinar: Preservatives in Pharmacy Compounding

November 15-17: Personalized Medicine Certification Course 1: Endocrinology in St. Pete Beach, Fla.

December 4:  PCAC meeting on adding several bulk drug substances to the 503A Bulks List (2 of 2)

December 13: APC Board of Directors Meeting, Las Vegas

December 13-15: A4M Longevity Fest, Las Vegas

APC In the News

Echoing our position:

Specialty Pharmacy Continuum has a great piece on the importance of a longer "tail" for 503As.

Wired story isn’t perfect, but…:

This time Wired missed the mark on pharmacy compounding, but it at least quoted Scott and focused on the important issues.

Wired focuses on GLP-1 patient fallout:

Wired looks at how some patients are being hit hard by tirzepatide coming off shortage.

Quartz mentions APC:

Not a big deal, but it shows we're getting media coverage across the spectrum.

San Diego news radio focuses on GLP-1 price:

It could have chosen any angle, and it went with the high price of commercial versions. 👍🏻

CNN gets it spot on:

The article, which of course quotes APC, focuses on the impact on patients of tirzepatide coming out of shortage.

Medscape focuses on compounders:

Medscape is the latest news outlet to cover tirzepatide, and it focuses on APC's perspective.

Commenting on the tirzepatide announcement:

Since the FDA announced that tirzepatide is (for now) out of shortage, APC's Scott Brunner has been all over the news offering our perspective.

Talking about those legal threats:

Baseless but time-consuming lawsuit threats make compounders shy.

APC does its best in a Hill article:

The piece spends a lot of time considering misconceptions about compounded GLP-1s, but it least it included a little straight info from Scott.

Weighing in on Lilly’s tirzepatide vials:

Scott tells Medscape that actually helping patients with vial-based tirzepatide is a welcome change for Lilly.

Shortage compounding is not a loophole, Scott explains to Axios:

"It is absolutely intentional policy on the part of FDA."

Click here for more examples of APC in the news

Support Compounding

Our Patrons